Original article

Barriers to implementing the “2008 Mexican Clinical Practice Guideline recommendations for the management of hip and knee osteoarthritis” in primary healthcare practice

Adalberto Loyola-Sanchez a,*, Julie Richardson a, Ingris Pelaez-Ballestas b, José Guadalupe Sánchez c, Martha Alicia González c, Juan Sánchez-Cruz d, María Valeria Jiménez-Baez e, Nancy Nolasco-Alonso f, Idolina Alvarado g, Jacqueline Rodriguez-Amado h, José Alvarez-Nemegyei i, Mike G. Wilson i

a School of Rehabilitation Science, McMaster University, Hamilton, Canada
b Centro Universitario de Salud, Universidad Autónoma de Nuevo León, Monterrey, Mexico
c Unidad de Medicina Familiar No. 1.4-Quintana Roo, Instituto Mexicano del Seguro Social, Cancún, Mexico
d Unidad de Medicina Familiar No. 60, Instituto Mexicano del Seguro Social, Estado de México, Mexico
e Centro de Salud “Independencia”, Servicios de Salud Morelos, Jiutepec, Mexico
f Hospital Universitario de Nuevo Leon “Jose Eleuterio Gonzalez”, Monterrey, Mexico
g Escuela de Medicina, Universidad Andihuac-Mayab, Mérida, Mexico
h McMaster Health Forum, Department of Clinical Epidemiology and Biostatistics, McMaster University Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Canada

Article history:
Received 3 October 2013
Accepted 17 January 2014
Available online xxx

Keywords:
Osteoarthritis
Hip
Osteoarthritis
Knee
Practice guidelines as Topic Mexico

Abstract

Objective: To evaluate the implementability of the “2008 Mexican Clinical Practice Guideline for the management of hip and knee osteoarthritis at the primary level of care” within primary healthcare of three Mexican regions using the Guideline Implementability Appraisal methodology version 2 (GLIA.v2).

Methods: Six family physicians, representing the South, North, and Central Mexico, and one Mexican psychiatrist evaluated the 45 recommendations stated by the Mexican guideline. The GLIA.v2 methodology includes the execution of qualitative and semi-quantitative techniques.

Results: Reviewers’ agreement was between moderate to near complete in most cases. Sixty-nine percent of the recommendations were considered difficult to implement within clinical practice. Eight recommendations did not have an appropriate format. Only 6 recommendations were judged as able to be consistently applied to clinical practice. Barriers related to the context of one or more institutions/regions were identified in 25 recommendations. These barriers are related to health providers/patients’ beliefs, processes of care within each institution, and availability of some treatments recommended by the guideline.

Conclusions: The guideline presented problems of conciseness and clarity that negatively affect its application within the Mexican primary healthcare context. We identified individual, organizational and system characteristics, which are common to the 3 institutions/regions studied and constitute barriers for implementing the guideline to clinical practice. It is recommended that the 2008-Mexican-CPG-OA be thoroughly revised and restructured to improve the clarity of the actions implied by each recommendation. We propose some strategies to accomplish this and to overcome some of the identified regional/institutional barriers.

Abbreviations: 2008-Mexican-CPG-OA, 2008 Mexican clinical practice guideline for the management of osteoarthritis at the primary level of care; TAO, Technical Aids and Orthotics; COX-2, cyclooxygenase 2; CPG, clinical practice guidelines; dec, decidability; exe, executability; fle, flexibility; GLIA, guideline implementability assessment instrument; CH, Clinical History; IMSS, Mexican Institute of Social Security; mea, measurability; nov, novelty or innovation; NSAIDs, non-steroid anti-inflammatory drugs; OA, osteoarthritis; pro, effect on process of care; R, reference to the 2nd level of care; SS, Mexican Secretary of Health; PT, Pharmacologic treatment; NPT, Non-pharmacologic treatment; val, validity.

* Corresponding author.
E-mail address: loyola@mcmaster.ca (A. Loyola-Sanchez).

© 2013 Elsevier España, S.L. All rights reserved.
Barreras para la implementación de la «Guía Mexicana de Práctica Clínica para el manejo de osteoartritis de cadera y rodilla en el primer nivel de atención 2008» en la práctica de atención primaria

RESUMEN

Objetivo: Evaluar las barreras de implementación de la guía de práctica clínica para el manejo de osteoartritis de cadera y rodilla en el primer nivel de atención 2008 dentro de la práctica clínica de 3 regiones mexicanas, usando la metodología Guideline Implementability Appraisal version 2 (GLIA v2).

Métodos: Seis médicos familiares, representantes del sur, norte y centro de México, y un médico rehabilitador mexicano evaluaron las 45 recomendaciones propuestas en la guía de práctica clínica. La metodología GLIA v2 incluye la ejecución de técnicas cualitativas y semicuantitativas.

Resultados: En su mayoría, el acuerdo entre revisores fue de moderado a casi completo. El 69% de las recomendaciones fueron consideradas como difíciles de implementar en la práctica clínica. Ocho recomendaciones no tienen un formato apropiado. Únicamente 6 recomendaciones pueden ser aplicadas consistentemente en la práctica clínica. En 25 recomendaciones, se detectaron barreras de implementación relacionadas al contexto de una o más de las instituciones/regiones exploradas. Estas barreras se relacionan con las creencias de proveedores de salud y pacientes, procesos de atención en cada institución y disponibilidad de algunos de los tratamientos recomendados en la guía.

Conclusiones: La guía contiene recomendaciones poco claras y concisas, lo que afecta negativamente a su aplicación dentro del primer nivel de atención mexicano. Identificamos características individuales, organizacionales y sistemáticas, comunes a las 3 instituciones/organizaciones estudiadas, que significan barreras para implementar la guía en México. Se recomienda que esta guía sea revisada y reestructurada con el fin de mejorar la claridad de sus recomendaciones. Proponemos algunas estrategias para hacer esto y atacar algunas de las barreras identificadas relacionadas dentro de las regiones exploradas.

© 2013 Elsevier España, S.L. Todos los derechos reservados.
The family physicians formed three teams representing different geographical regions and institutions: (1) the Northern team formed by two physicians from the SS-Monterrey, Nuevo León; (2) the Central team formed by one physician from the SS-Jiutepec, Morelos, and one physician from the IMSS-Tlalnepantla, Estado de México; and (3) the Southern team formed by one physician from the IMSS-Mérida, Yucatán, and one physician from the IMSS-Cancún, Quintana Roo. These physicians had at least one-year experience treating patients with knee and/or hip OA, had sufficient English language skills to follow the GLIA methods, and were prepared to commit enough time to complete the project. The physiatrist (AL) is from Mexico City and was in charge of the other reviewers’ training on the GLIA v2 application. In addition, he facilitated and coordinated communications within and across the teams. All family physicians completed a questionnaire inquiring about the following: a) their level of experience with health research, b) their previous knowledge about the existence of the 2008-Mexican-CPG-OA, c) their previous training on this CPG application, d) their previous training on OA management, and e) the percentage of weekly consultations dedicated to manage people with OA.

**2008-Mexican-CPG-OA**

The Mexican Secretary of Health coordinated the development of the 2008-Mexican-CPG-OA, collaborating with other Mexican public institutions. The main objective was to standardize the management of hip and knee OA within primary care, providing the best evidence available to manage the progression and disabling effects of these chronic conditions in Mexico. The recommendations stated in this CPG came from statements found in 5 international CPGs (1 Latin American, 1 North American, 2 Western European and 1 multinational) and 1 program implementation study. The Mexican CPG contains 45 recommendations structured in 5 main sections: “Medical History”, “Non-pharmacologic treatment”, “Pharmacologic treatment”, “Technical Aids and Orthotics”, and “Referral to a secondary level of care”. The “Non-pharmacologic treatment” section is further divided into: physical agents, weight reduction, therapeutic exercise, electrotherapy, and dietary supplements. The “Pharmacologic treatment” section is further divided into oral analgesics, and topical analgesics.

**GLIA v2**

The GLIA v2 instrument was developed to systematically identify barriers to implement CPGs’ recommendations. This instrument was created from a broad review of the factors that impact the success of guidelines’ use within the literature, and has been utilized to improve guideline recommendations. The GLIA is formed by 30 questions, 9 to evaluate global quality and 21 to assess the barriers for implementation of each individual recommendation. Details of the content and execution of this instrument are provided elsewhere. Briefly, each recommendation is assessed for its executability, decidability, validity, flexibility, effect on the process of care, measurability, novelty, and computability. We did not use the computability dimension, because we were not interested in the implementation of the Mexican CPG in electronic format.

**Procedure for the guideline’s evaluation**

We coded the 45 recommendations, giving each a unique identification number (see Appendix A). Initially, each team member worked individually on the guideline evaluation and then discussed his/her results with the other member of his/her team. The physiatrist moderated this discussion in person. All communications were conducted either through personal meetings, televideo conferencing or electronic mail during 4.5 months (see Fig. 1). Disagreements were solved through two rounds of discussion and the application of the “70% agreement” rule, meaning that each member expressed at least 70% satisfaction with what was agreed.

All reviewers gave permission to audio-record the meetings. The global quality of the guideline was determined through consensus from all members of all the teams because the guideline’s overall quality depends on its consideration to the Mexican context as a whole.

**Analysis**

Agreement between each team of reviewers was evaluated by calculating nominal data kappa coefficients using an on-line tool. We used these coefficients to judge agreements as follows: poor =<0.2, fair =0.21–0.4, moderate =0.41–0.6, strong =0.61–0.8, and near complete =0.8. We assessed each team’s responses to GLIA questions 10 to 26 in all 45 recommendations. The identified barriers to implementation were classified as either general or context-related. General barriers were defined as those related to the intrinsic structure of a recommendation; these are barriers for the executability, decidability, validity, flexibility and measurability of a recommendation. Context-specific barriers were defined as those related to the teams’ institution or region and are barriers related to novelty of the recommendation or to the process of care of each specific site. A synthesis of each recommendation’s barriers for implementation, along with strategies for addressing them, was then created. All team members reviewed this synthesis and confirmed its validity.

Following GLIA recommendations, we considered all recommendations with executability and/or decidability barriers as “not possible to implement” in a consistent way within clinical practice. In addition, we considered that all recommendations without a clear action implied within their statements should be eliminated from the guideline or transformed into an implementable recommendation. Refer to Table 1 for some examples of analytic interpretations performed by reviewers.

**Results**

The reviewers had been practicing family medicine for an average of 17 years (min = 7, max = 27) and dedicate 5–30% of their weekly clinical time to the management of OA. All reviewers were familiar with evidence-based practice concepts, and 4 reviewers were undertaking postgraduate studies in health research methodology. Two reviewers were aware of the existence of the 2008-Mexican-OA-CPG before starting this project; none of them had received training for implementing this guideline. Only one reviewer, from the Northern team, had taken formal training on OA management.

There was more moderate to near-complete agreement (n = 81) than poor to fair agreement (n = 41) in the assessment of each recommendation within all the teams (see Fig. 2). This trend did not change when considering the agreement of each team separately. Some calculated kappa coefficients were negative.

All teams agreed that the guideline clearly defined the target population and audience and has a format that allows for an easy identification of the recommendations. However, we detected important problems with the settings’ description, the guideline developers’ representativeness, and the recommendations’ sequence, internal consistency and conciseness (see Table 2).

The general and context-related barriers for implementation identified for each recommendation, along with their proposed
solutions, are described in Tables 3 and 4. Thirty-one recommendations presented executability and/or decidability problems that make them difficult to be applied consistently to clinical practice. Eight recommendations were just statements which contained no actions, so they do not have an appropriate recommendation format. Only six recommendations were judged as appropriate to be applied consistently to clinical practice in their current format (see Table 5).

The three teams agreed that the guideline does not provide a clear description of how the strength of the recommendations was determined. Although the guideline mentions the strength for each recommendation, the criteria used to adjudicate this strength are not explained in the document. The nomenclature to describe recommendations’ strength is inconsistent; sometimes it is through letters and sometimes through numbers. In addition, information about how the guideline developers chose the recommendations from the different CPGs used to create this guideline is also not described in the document.

Twenty-five recommendations were identified with barriers related to the context of one or more of the institutions-regions represented in this project. The Northern team identified barriers mainly related to health providers’ beliefs and patients’ expectations. The Central team identified barriers related to the process of care and treatment availability. The Southern team identified
Table 1  Examples of reviewers' analytic interpretations.

<table>
<thead>
<tr>
<th>Statement without a recommendation format</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT8: There is no evidence to support the use of tricyclic anti-depressants in osteoarthritis pain</td>
<td>Reviewers agreed that there is no action implicated in this statement; hence, this is not a recommendation and should be eliminated from the guideline.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation with general barriers</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT10: Paracetamol should be considered for the management of osteoarthritis, after the use or in continuity with NSAIDs, COX-2 or opioids</td>
<td>Reviewers agreed that this recommendation has executability problems because the circumstances in which paracetamol prescription goes “after” or goes “along with” NSAIDs, COX-2 or opioids are not clear. There are no details on the paracetamol dosage. The consistent implementation of this recommendation is not possible. This recommendation has validity issues because justification for the recommendation is not explicitly stated in the guideline. This recommendation contradicts the information given in the quick guide in which paracetamol appears as the first choice of pharmacological treatment for knee and hip OA.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recommendation with context-specific barriers</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPT14: Electro-acupuncture should not be used in the management of people with osteoarthritis</td>
<td>SS-Monterrey reviewers agreed that this recommendation has novelty problems because it goes against the beliefs of some people living in Monterrey. The use of electrotherapy and acupuncture is fairly common; therefore, it is important to design patient education strategies directed to avoid the use of these therapeutic modalities, providing a strong and clear justification.</td>
</tr>
</tbody>
</table>

GLIA, Guideline Implementability Assessment Instrument; PT8, recommendation number 8 from the “Pharmacologic treatment” section; NSAIDs, Non-steroid anti-inflammatory drugs; COX-2, cyclooxygenase 2 inhibitors; PT10, recommendation number 10 from the “Pharmacologic treatment” section; NPT14, recommendation number 14 from “Non-pharmacologic treatment” section; SS, Monterrey-Mexican Health Secretary of Monterrey.

Table 2 2008-Mexican-OA-CPG’s Global Quality Evaluation.

<table>
<thead>
<tr>
<th>GCQ</th>
<th>Answer</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Y</td>
<td>The target population is clearly identified in the document.</td>
</tr>
<tr>
<td>2</td>
<td>Y</td>
<td>The target audience is clearly identified in the document.</td>
</tr>
<tr>
<td>3</td>
<td>N</td>
<td>The settings in which several recommendations should be applied are not described. Some recommendations are not even applicable to the Mexican primary healthcare context. It is necessary to provide a clear description of each recommendation’s setting in order to assure the consistency of the guideline’s application.</td>
</tr>
<tr>
<td>4</td>
<td>N</td>
<td>Health providers such as, rheumatologists, orthopedic surgeons, nurses, physiotherapists, occupational therapists, and users were not represented in the group of guideline developers.</td>
</tr>
<tr>
<td>5</td>
<td>Y</td>
<td>The guideline includes a “quick guide”. However it is not very useful, because it includes information that contradicts the full version, and includes information not provided in the complete guideline.</td>
</tr>
<tr>
<td>6</td>
<td>N</td>
<td>There is no sequential logic in the form the recommendations are presented. Some recommendations are repetitive, affecting the understandability of the guideline. It is important to build a sequence in the recommendations; the algorithm provided in the quick version can help with this structuring.</td>
</tr>
<tr>
<td>7</td>
<td>N</td>
<td>There are some contradictions between the evidence presented and the recommendations stated. There are evidence statements without recommendations and recommendations without evidence statements.</td>
</tr>
<tr>
<td>8</td>
<td>Y</td>
<td>The guideline format allows for an easy identification of the recommendations.</td>
</tr>
<tr>
<td>9</td>
<td>N</td>
<td>Several recommendations are ambiguous regarding the action contained. There are many recommendations with repetitive information.</td>
</tr>
</tbody>
</table>

Barriers related to the process of care, and patients’ expectations. We also identified common barriers related to the context of the three institutions-regions represented in the study (see Tables 3 and 4).

Discussion

This study uncovered some aspects of the 2008-Mexican-CPG-OA that can impede its successful implementation within the IMSS-Estado de México, Quintana-Roo and Yucatán, and in the SS-Morelos and Nuevo León. As a whole, the guideline presented problems of conciseness and clarity that negatively affect its credibility and application within the Mexican primary healthcare context. Only 6 of the 45 recommendations (14%) were considered to be implementable in a consistent way. We also detected differences and similarities in the identified context-related barriers for implementation among the three institutions and regions represented in this project. Finally, we were able to propose some strategies to increase the guideline’s successful implementation within Mexican clinical practice.

Clinical practice guidelines synthesize and inform the best available knowledge to support decision-making processes in clinical healthcare. The developers of the 2008-Mexican-CPG-OA created this guideline not only to aid in the decision-making process of primary caregivers but also to “standardize national actions” regarding the management of knee and hip OA in Mexico. The standardization of clinical practice at a national level could be an ambitious goal for a CPG. The guideline presents some issues regarding its structure, recommendations’ clarity and developers’ credibility, all of which may affect its utility for supporting decisions, making the standardization of clinical practice within the primary care of Mexico difficult.

The guideline’s structure does not allow for a clear understanding of the settings and the sequence in which recommendations should be applied. It has been observed that CPGs without comprehensible structure are not easy to implement during everyday practice. Furthermore, most of the recommendations stated in this guideline are neither consistent nor concise, and it is difficult to understand the required actions implicit within them. The literature shows that in practice, vague recommendations are literature less utilized than recommendations that clearly state what to do. On the other hand, reviewers expressed concern about the guideline developers’ credibility, noting that some knowledge users and patients were not involved in the guideline creation. A literature review on OA management conducted in Mexico, concluded that management of people with OA should be multi-disciplinary, including rheumatologists, orthopedic surgeons and nutritionists, none of whom were represented in the creation of the 2008-Mexican-CPG-OA.
Table 3
General and context-related barriers for implementation and possible solutions: Medical History (CH) and Non-pharmacologic treatment (NPT).

<table>
<thead>
<tr>
<th>Guideline section</th>
<th>G(^a)</th>
<th>C</th>
<th>Proposed solutions(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical History</td>
<td>exe fle val</td>
<td>None</td>
<td>Define in: 1, how to assess “activity limitations” and conduct “physical assessment”; 2, meaning of “high doses” and “chronic use”. Change “warfarin” for “anticoagulants” in 2. Clarify meaning of “Age &gt; 60 years” in 3. Provide justification for 1, 2 and 3.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe fle val dec</td>
<td>pro nov mea</td>
<td>2 and 3 are not recommendations. Create one recommendation from 3 defining “good communication” and expected outcomes; three recommendations from 4; two recommendations from 5 detailing “weight reduction” “joint protection” “education” and “advice” and conditioning to overweight or obese people. Define in: 1, how to do “joint decision making” and what to do for people with no decision capacity; 6, content of “exercises”, “self-management”, “physical” and “occupational therapy”, “functional limitations”, what to do with people without functional limitations, and who is responsible for prescription/execution. Provide justification for 1, 4, 5 and 6. In the 3 regions/institutions: Design training strategies for exercise prescription, self-management and OA rehabilitation. Allow more time per consult. Build or improve existing primary care rehabilitation units.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe fle val</td>
<td>pro nov mea</td>
<td>For 7: Define details on “cryotherapy” and “superficial heat” prescription; who should receive these interventions and for what purpose; and who is responsible for prescribing and applying them. Provide justification for this recommendation.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe fle val dec</td>
<td>None</td>
<td>Merge 8 and 9. Define how much weight reduction is recommended; monitoring strategies; meaning of “low levels”; and person’s characteristics that allow individualization. Provide justification. Include persons with obesity.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe fle val</td>
<td>pro nov</td>
<td>10 is not a recommendation. Merge first part of 12 with 11 and create a single recommendation for “pool exercises”. Define prescription details and who is responsible for prescribing this. Provide justification.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe fle val</td>
<td>pro nov mea</td>
<td>In the 3 regions/institutions: Build primary care rehabilitation units including therapeutic pools. Design training strategies for exercise prescription. Define in 13, TENS prescription details and who is responsible for it. Provide justification for using indirect evidence to state 14 (evidence for acupuncture was extrapolated to electro-acupuncture). In the 3 regions/institutions: Design training strategies on TENS prescription and assure devices’ availability. In S5-Monterrey: Design patient-education strategies to avoid use of electro-acupuncture.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe fle val</td>
<td>pro</td>
<td>For 15 Define “glucosamine” and “condroitin sulfate” dosages. Provide justification for recommending an intervention that is “no better than placebo” as described by the “evidence boxes” of the guideline.</td>
</tr>
<tr>
<td>Non-pharmacologic</td>
<td>exe val supplements</td>
<td></td>
<td>In the 3 regions/institutions: Assure the availability of glucosamine and condroitin sulfate.</td>
</tr>
</tbody>
</table>

CH, Clinical History; NPT, Non-pharmacologic treatment; G, general barriers; C, context-related barriers; exe: executability (recommendation says exactly what to do); fle: flexibility (degree to which a recommendation permits interpretation allowing for execution alternatives); dec: decidability (recommendation says precisely under what conditions to do something); pro: effects on process of care (degree to which a recommendation impacts the usual workflow in a typical care setting); nov: novelty (degree to which a recommendation proposes unconventional behaviors for clinicians or patients); mea: measurability (degree to which markers of a recommendation’s effects are available); TENS: Transcutaneous Electrical Neurostimulation.

\(^a\) The strength of all recommendations is not explicitly stated.

\(^b\) Recommended actions within solutions are in italics. Bold numbers identify each recommendation within each guideline’s main section (refer to Appendix 1, “The coded 2008 Mexican-CPG-OA” to read each recommendation’s content).

Increasing evidence shows that involving patients and knowledge users in the development of a CPG improves its applicability to clinical practice. Consequently, we think it is necessary to restructure the 2008-Mexican-CPG-OA replacing ambiguous recommendations for behavior-specific statements that clarify the what, who, when, where and how of the intended actions. This restructuring process should also include representatives from patients, primary care clinicians, rheumatologists and orthopedic surgeons. We also suggest that the quick guide (see Table 2) should be restructured, ensuring that its content matches the contents of the complete guideline.

The vast majority of the guideline’s recommendations (86%) presented executability and/or decidability problems, which implies great challenges for its consistent implementation to the Mexican context. Failed executability and decidability are often the result of vagueness in the description of the actions involved in a recommendation. This vagueness results in application inconsistencies that go against the standardization purposes of a guideline. Interestingly, the 2008-Mexican-CPG-OA recommendations preserved the original foreign CGPs’ format. This may suggest that problems observed in the implementation of some of these foreign CGPs in countries such as France, Canada, and the UK are due to executability and decidability issues.

Only two of the six recommendations judged to be implementable in their current form (see Table 5) address one of the eight actions recently proposed as the minimum standard of care for people with knee and hip OA, “to minimize individual risk potential for NSAIDs harms”. The Mexican CPG considers all of these standard actions of care. This suggests that a simple restructuring of the recommendations can potentially result in an improvement in the quality of care for people living with OA in Mexico.

Apparently, the values used to define the strength of the recommendations in the 2008-Mexican-CPG-OA were based on study design. Nevertheless, it has been widely recognized in the literature that the strength of CPG recommendations should not only reflect the quality of supporting evidence, but also the values and beliefs of developers, considering the context. Moreover, it has been strongly recommended that the processes to determine the strength of a recommendation be described in a transparent way. Consequently, we urge the guideline developers to be more explicit about the procedures they followed to state the recommendations’ strength, so the audience can judge their validity.

The context-related barriers identified can be further categorized as individual, organizational or system related. The Northern team identified individual barriers, the Central team identified organizational and system-related barriers, and the Southern team identified individual, organizational and system-related barriers. This shows how the context could influence the implementability of a recommendation, supporting the argument that CGPs have to be adapted to local conditions. Furthermore, the
<table>
<thead>
<tr>
<th>Guideline section</th>
<th>G&lt;sup&gt;a&lt;/sup&gt;</th>
<th>C</th>
<th>Proposed solutions&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacologic treatment: oral analgesics</td>
<td>exe fle val dec</td>
<td>pro nov</td>
<td>8 is not a recommendation. Describe how the strength of 1 was judged. Define in: 2, action proposed, how to monitor &quot;risk factors, and meaning of &quot;adequate monitoring&quot;; 3, meaning of &quot;risks for NSAIDs&quot;, actions proposed for &quot;not at risk&quot; people and persons' characteristics that allow for individualization; 4, when to use &quot;NSAIDs&quot; and when &quot;COX-2 inhibitors considering those patients in whom both paracetamol and topical NSAIDs are not effective; 5, meaning of &quot;minor effective doses&quot; and &quot;shorter periods of time&quot; and patients' characteristics that allow for individualization; 6, meaning of &quot;risk for NSAIDs&quot; and what to do with people at risk for NSAIDs but no gastrointestinal bleeding; 7, meaning of &quot;cardiovascular diseases&quot; and &quot;being very careful&quot;; 9, opioids and narcotics dosage and patients' characteristics for individualization; 10, paracetamol dosage and in what circumstances this is used &quot;after&quot; or &quot;along with&quot;; 11, meaning of &quot;risk&quot; and &quot;benefits&quot; and how to assess these; 12, how to modify paracetamol doses and monitor &quot;risk for toxicity&quot;; 13, dosage of all interventions and patients' characteristics that allow for individualization. Explain in: 3, why a previous imperative recommendation (1) is converted into a conditional recommendation; 6, if the intention is to prescribe COX-2 inhibitors during an active gastrointestinal bleeding episode; 7, why the evidence provided on &quot;diclofenac&quot; extends to all NSAIDs; 10, the contradiction with the &quot;quick guide&quot; in which paracetamol is the first line of pharmacological treatment. Provide justification for 4, 5 and 13. Divide: 7 in two: 7a for &quot;cardiovascular diseases&quot; and 7b for &quot;minimal effective doses&quot; and &quot;gastric protector&quot;; 12 in two: 12a for &quot;paracetamol dosage&quot; and 12b for &quot;toxicity modification&quot;. Merge: 7b with 1, 3 and 5, and 11 with 9. In the 3 regions/institutions: Assume availability of COX-2 inhibitors, weak opioids and narcotics. Design prescription-training strategies. In SS-Monterrey: Design dissemination strategies to prescribe COX-2 during active gastrointestinal bleeding.</td>
</tr>
<tr>
<td>Pharmacologic treatment: topical analgesics</td>
<td>exe fle val dec</td>
<td>pro</td>
<td>17 is a recommendation. Define in: 14, cap sin dosage and indications; 15 and 16, which topical NSAIDs should be considered, what doses and how can they be combined with &quot;basal treatment&quot; and paracetamol; 18-how capsacin should be combined with &quot;basal treatment&quot;. Merge: 15 with 16 and 14 with 18. Provide justification for 14, 15, 16, 18 and 19. Explain why 15, 16 and 18 are conditioned only to knee OA including alternatives for hip OA. In IMSS-Merida, Cancun, and Edo. Mex: Assume availability of topical capsacin and NSAIDs.</td>
</tr>
<tr>
<td>Technical Aids and Orthotics</td>
<td>exe fle val</td>
<td>pro</td>
<td>4 and 5 are not recommendations. Create two recommendations on the use of &quot;splitting&quot; and &quot;shoe insoles&quot; defining prescription details. Define in: 1, which &quot;orthoses&quot;, patients' characteristics that allow individualization and who is in charge of prescribing them; 2, further instructions for &quot;cane and walker&quot; prescription allowing for individualization; 3, meaning of &quot;appropriate footwear&quot;, and who is responsible for prescription. In the 3 regions/institutions: Design training strategies for orthoses, cane/walker, and footwear prescription. Assume availability of orthoses, canes and walkers. Build or improve existing primary care rehabilitation units.</td>
</tr>
<tr>
<td>Reference to 2nd level of care</td>
<td>fle val dec</td>
<td>pro nov</td>
<td>3 is a recommendation. Explain why only patients with functioning states II and IV should be referred to a 2nd level of care. Define in 2 meaning of &quot;adequate pain relief&quot; and &quot;functional improvement&quot; allowing for individualization. Provide justification for 2 adding the &quot;referral&quot; action. In the 3 regions/institutions: Design training strategies for &quot;functional capacity&quot; evaluation, and patient education strategies to change negative beliefs around joint replacement. Improve efficiency of referral processes.</td>
</tr>
</tbody>
</table>

PT, Pharmacologic treatment; TAO, Technical Aids and Orthotics; R, Referral to second level of care. G, general barriers; C, context-related barriers. exe: executability (recommendation says exactly what to do); fle: flexibility (degree to which a recommendation permits interpretation allowing for execution alternatives); val: validity (degree to which a recommendation reflects the intent of developers and strength of evidence); dec: decalibility (recommendation says precisely under what conditions to do something); pro: effects on process of care (degree to which a recommendation impacts upon the usual workflow in a typical care setting); nov: novelty (degree to which a recommendation proposes unconventional behaviors for clinicians or patients); mea: measurability (degree to which markers of a recommendation's effects are available); NSAIDs: Non-Steroid Anti-Inflammatory Drugs; COX-2: Cyclooxygenase 2; SS-Mexican Health Secretary; IMSS, Mexican Institute of Social Security.

<sup>a</sup> The strength of all recommendations is not explicitly stated.

<sup>b</sup> Recommended actions within solutions are in italics. Bold numbers identify each recommendation within each guideline’s main section (refer to Appendix 1, “The coded 2008-Mexican-CPG-OA” to read each recommendation’s content).

There were some issues during the application of the GLIA v2 methodology in this study. All reviewers had problems with the concept of flexibility. Flexibility is defined as “the degree to which a recommendation permits interpretation and allows for alternatives in its execution.” This seems to be opposed to the idea of “consistency” evaluated in the executability dimension. After some discussion, team members concluded that “flexibility” favors the implementability of a recommendation allowing for consistent tailoring and does not imply an “anything goes” approach. Moreover, all teams agreed that the recommendation’s strength does not belong to “flexibility” but to the validity dimension of the GLIA v2. It was difficult for some reviewers to differentiate between conditional and imperative recommendations and for discerning which statements were not recommendations. These difficulties resulted in negative kappa coefficients during aggregation analyses, meaning less agreement than expected by chance.
In spite of this, all reviewers agreed that the application of the GLIA v2 instrument, although time-consuming, was very helpful to stimulate consideration about guideline implementation barriers, allowing them to reflect on their clinical practices. We think that the GLIA v2 methodology can be further improved by (1) clarifying the dimension of flexibility, (2) providing examples that demonstrate differences among dimensions, (3) providing examples that show the difference between conditional and imperative recommendations, and (4) adding criteria to allow for the identification of statements, which are not recommendations.

One of the limitations of this study is the small number of physicians involved in the guideline evaluation process, which affects the generalizability of the results. However, the 6 family physicians involved had experience managing people with knee or hip OA, representing the two largest public health institutions of Mexico across 3 large geographical regions. Moreover, involving physicians who were currently in research training ensured the quality of the evaluations and analyses. Another limitation is that we did not evaluate the actual success in the implementation of the recommendations at the primary level of care. Consequently, we deduced that the 2008-Mexican-CPG-OA is not consistently implemented in clinical practice due to problems with the executability and decidability of its recommendations. Obviously, this deduction needs to be further evaluated.

In conclusion, the 2008-Mexican-CPG-OA has important barriers to its consistent implementation within the IMSS of Estado de México, Quintana Roo and Yucatán, and in the SS of Morelos and Nuevo León. We recommend that this guideline undergo thorough revision and restructuring to improve the clarity of the actions implied in each recommendation. We propose some strategies to facilitate this revision, along with some implementation activities to address individual, organizational and system-related barriers. These efforts will potentially increase the success in the 2008-Mexican-CPG-OA’s implementation, improving the standard of care for Mexican people living with knee and hip osteoarthritis.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

All authors declare no conflicts of interest.

Acknowledgements

We thank Dr. Thelma Martínez Villareal, Dr. Mario Garza and Dr. Jorge Esquivel Valerio from the research department of the School of Medicine at the Universidad Autónoma de Nuevo León for their invaluable input and support during the conduction of this study. Adalberto Loyola-Sanchez is a recipient of a CONACYT (Consejo Nacional de Ciencia y Tecnología) scholarship for foreign studies and a CIHR (Canadian Institute for Health Research) Vanier scholarship. Travel expenses were partially covered by a School of Rehabilitation Science graduate bursary.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.reuma.2014.01.010.

References


Table 5

Recommendations considered as ready to be implemented in clinical practice.

<table>
<thead>
<tr>
<th>Rec ID</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH2</td>
<td>“The gastrointestinal risk evaluation in people with OA should include: (a) Gastrointestinal bleeding history, (b) Peptic ulcer history or steroid-induced gastrointestinal symptoms, (c) Current use of corticosteroids and warfarin.”</td>
</tr>
<tr>
<td>NPT14</td>
<td>“Electro acupuncture should not be used in the management of people with osteoarthritis.”</td>
</tr>
<tr>
<td>PT1</td>
<td>“When osteoarthritis is treated with oral NSAIDs or COX-2 inhibitors, a proton-pump inhibitor should be prescribed, selecting the least costly.”</td>
</tr>
<tr>
<td>PT19</td>
<td>“Topic rubefacients (trolamine salicylate and cooper salicylate) are not recommended for the management of osteoarthritis.”</td>
</tr>
<tr>
<td>TAO2</td>
<td>“Walking aids reduce pain in patients with hip and knee osteoarthritis. Patients should be instructed on the optimal use of a cane with the arm opposite to the affected joint. Walkers with wheels are recommended in the cases of bilateral affection.”</td>
</tr>
<tr>
<td>R1</td>
<td>“Patients with hip and knee osteoarthritis with functional class III and IV (ARA) should be referred to a rehabilitation unit to receive an evaluation and program prescription from a physical therapist or a physician specialized in Physical Medicine and Rehabilitation, who will use different therapeutic modalities such as electrotherapy or therapeutic exercises to decrease their pain and improve their functional capacity. A successful rehabilitation program could avoid the need of walking aids such as canes and walkers.”</td>
</tr>
</tbody>
</table>


